Physician profile
Julia Riftine
NPI 1861685216
$3,062.32
in general payments reported to CMS, 2019-2025
24 companies · $167 in 2025
The $167 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $246 · 2020: $35.81 · 2021: $216 · 2022: $407 · 2023: $220 · 2024: $1,771 · 2025: $167.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,078 · Education: $80.10.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,077.81 |
| Education | $80.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lumenis Be INC | $1,249.41 | 2024 | M22 |
| Celularity INC. | $300.00 | 2022 | |
| Hologic Sales and Service, LLC | $256.56 | 2020-2024 | Myosure Tissue Removal Device |
| Millicent US INC | $222.89 | 2021-2025 | Femring, Intrarosa |
| Exeltis, USA INC. | $220.67 | 2019-2025 | Slynd |
| Abbvie INC. | $136.03 | 2019-2023 | Orilissa, Lo Loestrin Fe, Liletta |
| Astrazeneca Pharmaceuticals LP | $120.64 | 2024 | Farxiga |
| Revance Therapeutics, INC. | $100.20 | 2025 | Daxxify |
| Evofem Biosciences, INC. | $71.74 | 2021-2022 | |
| Astellas Pharma US INC | $64.23 | 2023-2024 | Veozah |
| Sumitomo Pharma America, INC. | $50.36 | 2024-2025 | Gemtesa, Myfembree |
| Lupin INC. | $48.10 | 2019-2021 | |
| Avion Pharmaceuticals | $35.75 | 2021-2022 | |
| Samsung Hme America, INC. | $30.00 | 2019 | |
| Avanos Medical | $19.90 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopersurgical, INC. | $17.64 | 2024 | Paragard T 380a |
| Roche Diagnostics Corporation | $17.47 | 2019 | |
| Aspira Women'S Health INC | $17.43 | 2019 | |
| Davol INC. | $15.27 | 2021 | |
| Vertical Pharmaceuticals, LLC | $15.00 | 2019 | |
| Allergan, INC. | $14.20 | 2019 | |
| Merck Sharp & Dohme LLC | $13.97 | 2019 | |
| Agile Therapeutics, INC. | $12.86 | 2022 | |
| Amag Pharmaceuticals, INC. | $12.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julia Riftine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.